Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
REPL
#3709
Replimune Group, Inc.
2.2
8
USD
+16.92%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+16.92%
Monthly Change
-69.44%
6 month change
-51.39%
Year Change
-70.08%
Previous Close
1.9
5
Open
2.2
8
Bid
Ask
Low
2.2
8
High
2.2
8
Volume
10
Markets
US Stock Market
Healthcare
REPL
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
77.09 M
78.06 M
78.44 M
82.57 M
—
Valuation ratios
Enterprise value
689.65 M
677.38 M
276.43 M
730.14 M
2.37 B
Price to earnings ratio
-3.18
-2.87
-1.21
-2.83
-10.08
Price to sales ratio
3 907.96
-1 340.23
-180.52
433.74
2 820.96
Price to cash flow ratio
-4.09
-3.56
-1.4
-3.13
-12.17
Price to book ratio
1.89
0.48
0.24
0.69
3.3
Enterprise value to EBITDA ratio
-2.68
-2.33
-0.87
-2.28
-8.16
Profitability ratios
Return on assets %
-0.13
-0.18
-0.21
-0.21
-0.75
Return on equity %
-0.18
-0.26
-0.32
-0.34
-1.09
Return on invested capital %
-405.56
-448.15
-407.29
-347.75
-1 608.74
Gross margin %
100
100
100
100
400
Operating margin %
-7 547.57
15.3 K
-9 633.26
-12.37 K
-14.25 K
EBITDA margin %
-7 365.18
15.25 K
-9 441.83
-12.13 K
-13.69 K
Net margin %
-7 053.28
14.67 K
-9 497.14
-12.21 K
-14.09 K
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.95
6.94
6.31
5.6
26.8
Inventory turnover
—
—
—
—
—
Asset turnover
0
-0
0
0
0
Solvency ratios
Debt to assets ratio
0.09
0.11
0.13
0.15
0.47
Debt to equity ratio
0.12
0.15
0.19
0.24
0.7
Long term debt to total assets ratio
0.08
0.1
0.12
0.14
0.45
Long term debt to total equity ratio
0.11
0.14
0.18
0.23
0.66
Per share metrics
Operating cash flow per share
-0.67
-0.84
-0.88
-0.72
-3.11
EBIT per share
-0.97
-0.99
-0.91
-0.77
-3.65
EBITDA per share
-0.96
-0.98
-0.9
-0.76
-3.61
Total debt per share
0.61
0.54
0.54
0.55
2.24
Cash per share
6.01
4.41
3.52
2.92
16.85
Net current asset value per share
6.16
4.52
3.63
3.04
17.34
Tangible book value per share
5.16
3.68
2.86
2.28
13.99
Working capital per share
5.38
3.87
3.06
2.5
14.8
Book value per share
5.16
3.68
2.86
2.28
13.99
News
Replimune stock collapses 64% following FDA rejection
Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)
FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy